Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Apr 1;13(2):e2023130.
doi: 10.5826/dpc.1302a130. Online ahead of print.

Sorafenib-Induced Acute Generalized Exanthematous Pustulosis

Andrea Cortese  1   2 , Saverio Pancetti  3 , Tiziana Pressiani  4 , Francesco Toso  1   2 , Giovanni Fiorillo  1   2 , Antonio Costanzo  1   2 , Riccardo Giovanni Borroni  1   2
Affiliations

Sorafenib-Induced Acute Generalized Exanthematous Pustulosis

Andrea Cortese et al. Dermatol Pract Concept. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Competing Interests: None.

Figures

Figure 1
Figure 1
Confluent erythematous macules on his trunk and limbs, involving about 75% of the body surface area, d with overlying disseminated tiny non-follicular pustules.
Figure 2
Figure 2
Intraepidermal pustule containing fibrin and neutrophils; in the superficial dermis, a mixed inflammatory infiltrate composed scattered neutrophils and lymphocytes was present.
Figure 3
Figure 3
Naranjo Adverse Drug Reaction Probability Scale.
See this image and copyright information in PMC

References

    1. Sidoroff A, Halevy S, Bavinck JN, Vaillant L, Roujeau JC. Acute generalized exanthematous pustulosis (AGEP): a clinical reaction pattern. J Cutan Pathol. 2001;28(3):113–119. doi: 10.1034/j.1600-0560.2001.028003113.x. - DOI - PubMed
    1. Sidoroff A, Dunant A, Viboud C, et al. Risk factors for acute generalized exanthematous pustulosis (AGEP)-results of a multinational case-control study (EuroSCAR) Br J Dermatol. 2007;157(5):989–996. doi: 10.1111/j.1365-2133.2007.08156.x. - DOI - PubMed
    1. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–245. doi: 10.1038/clpt.1981.154. - DOI - PubMed
    1. Bracarda S, Ruggeri EM, Monti M, et al. Early detection, prevention and management of cutaneous adverse events due to sorafenib: recommendations from the Sorafenib Working Group. Crit Rev Oncol Hematol. 2012;82(3):378–386. doi: 10.1016/j.critrevonc.2011.08.005. - DOI - PubMed
    1. Liang CP, Yang CS, Shen JL, Chen YJ. Sorafenib-induced acute localized exanthematous pustulosis in a patient with hepatocellular carcinoma. Br J Dermatol. 2011;165(2):443–445. doi: 10.1111/j.1365-2133.2011.10377.x. - DOI - PubMed

LinkOut - more resources